Market Overview

Cellerant Therapeutics, Inc. Publishes Preclinical Data Highlighting Potential of its CLL1-Targeting Antibody-Drug Conjugate to Treat Acute Myeloid Leukemia


Cellerant Therapeutics, Inc., a clinical-stage company developing
innovative immunotherapies for hematologic malignancies and other
blood-related disorders, announced the publication of preclinical data
demonstrating the potential of CLT030,the Company's CLL1-targeting
antibody-drug conjugate (ADC), as a treatment for acute myeloid leukemia
(AML). The article appeared today in Blood Advances, a
semimonthly, peer-reviewed, online medical journal published by the American
Society of Hematology
and can be accessed at

CLT030 targets C-type-like lectin 1 (CLL1, also known as CLEC12A), a
cell surface antigen expressed in nearly all AML cell subtypes,
including leukemic stem cells, but not on normal hematopoietic stem
cells. This expression profile differentiates CLL1 from CD33, a common
target for targeted AML therapeutics, as it may allow faster
hematopoietic recovery in treated patents compared to a CD33-targeting
therapeutic. The preclinical data show CLT030 potently kills leukemic
stem and blast cells, and has less severe effects on normal
hematopoietic stem and progenitor cells compared to a CD33-targeting ADC.

"AML remains a significant unmet medical need, and an ADC that can
target leukemic stem cells precisely while minimally affecting normal
hematopoietic stem cells could improve outcomes while avoiding much of
the toxicities associated with conventional chemotherapy and other
targeted therapeutics," said Ram Mandalam, President and CEO of
Cellerant. "We look forward to advancing CLT030 to the clinic."

Cellerant's CLT030 development program is supported in part by a grant
from the California Institute for Regenerative Medicine (CIRM), an
agency of the State of California whose mission is to accelerate stem
cell treatments to patients with unmet medical needs.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical-stage company developing innovative
cell- and antibody-based immunotherapies for hematologic malignancies
and other blood-related disorders. Cellerant's romyelocel-L is a
universal cell therapy which does not require HLA matching intended to
prevent bacterial and fungal infections during neutropenia. In a
randomized, controlled Phase 2 clinical trial in AML patients,
romyelocel-L reduced infections and days in hospital. The romyelocel-L
program has been supported by federal funds from the Biomedical Advanced
Research and Development Authority (BARDA), Department of Health and
Human Services, under contract HHSO100201000051C. Cellerant is
developing two novel antibody drug-conjugate (ADC) products: CLT030 to
treat AML by selectively targeting and killing leukemic stem and blast
cells, and CSC012-ADC for hematologic malignancies and solid tumor
indications. For more information, visit:

View Comments and Join the Discussion!